In tumor immunosuppression, CAFs suppress host tumor immunity in vivo and in clinical practice; increased CD8+ tumor-infiltrating lymphocytes (TILs) and decreased forkhead box P3 (FoxP3)+ TILs are significantly correlated with CAFs and outcomes [20]. The gene discussed is FOXP3; the disease is neoplasm.